FDA
-
-
-
-
-
-
-
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
-
-
-
-
-
-
-
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
-
-
-
-
-
-
-
Pyxis Oncology (PYXS) Granted FDA Fast Track Designation for PYX-201
-
-
-
-
-
-
-
Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update
-
-
-
-
-
-
-
Axcella Therapeutics (AXLA) Announces Appointment of New CFO
-
-
325,129 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

